U-BLC1Homo sapiens (Human)Cancer cell line

Also known as: UBLC1

🤖 AI SummaryBased on 4 publications

Quick Overview

U-BLC1 is a human bladder cancer cell line with TERT promoter mutations and potential for bladder cancer research.

Detailed Summary

U-BLC1 is a human bladder cancer cell line with documented TERT promoter mutations, making it a valuable tool for studying telomerase activation mechanisms in bladder cancer. The cell line has been used in research to detect TERT mutations in bladder tumours and urine samples, contributing to the understanding of bladder cancer genetics and potential biomarkers for non-invasive surveillance. U-BLC1 is part of a panel of cell lines analyzed for TERT mutations, highlighting its relevance in bladder cancer research. The cell line's characteristics include a high frequency of TERT promoter mutations, which are associated with both non-muscle-invasive and muscle-invasive bladder cancers. These mutations are linked to increased TERT promoter activity, suggesting a critical role in tumorigenesis. U-BLC1's utility extends to preclinical studies, where it can be used to evaluate therapeutic strategies targeting telomerase activation. The cell line's molecular profile supports its use in investigating the relationship between TERT mutations and cancer progression, offering insights into potential therapeutic targets.

Research Applications

Study of TERT promoter mutations in bladder cancerDetection of TERT mutations in urine samplesInvestigation of telomerase activation mechanismsPreclinical evaluation of therapies targeting telomeraseAnalysis of TERT mutation frequency in bladder cancer

Key Characteristics

High frequency of TERT promoter mutationsRelevance to both non-muscle-invasive and muscle-invasive bladder cancersPotential biomarker for non-invasive surveillanceUse in preclinical therapeutic studies
Generated on 6/19/2025

Basic Information

Database IDCVCL_2738
SpeciesHomo sapiens (Human)

Donor Information

Age84
Age CategoryAdult
SexFemale

Disease Information

DiseaseBladder carcinoma
LineageBladder/Urinary Tract
SubtypeBladder Urothelial Carcinoma
OncoTree CodeBLCA

DepMap Information

Source TypeECACC
Source IDACH-000741_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Gln331Ter (c.991C>T)Homozygous-PubMed=29970484, PubMed=15287027
MutationSimpleTP53p.His296Tyr (c.886C>T)Homozygous-Unknown
MutationSimpleTERTc.1-124C>T (c.228C>T) (C228T)UnspecifiedIn promoterfrom parent cell line Hep-G2
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Systematic review: characteristics and preclinical uses of bladder cancer cell lines.

Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.

Bladder Cancer 4:169-183(2018).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Identification of mutations in distinct regions of p85 alpha in urothelial cancer.

Knowles M.A.

PLoS ONE 8:E84411-E84411(2013).

Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.

Hurst C.D., Platt F.M., Knowles M.A.

Eur. Urol. 65:367-369(2014).

Detailed marker chromosome analysis in cell line U-BLC1, established from transitional-cell carcinoma of the bladder.

Hameister H.

Int. J. Cancer 80:903-910(1999).